CooperCompanies Stock - Analyst consensus and long-term drivers

Edited by ad hoc news Long-Term & Business-Model Desk. Verified prior to publication on 06/20/2026, 16:43 UTC. Details in the imprint.

CooperCompanies (US21664P1039) remains a core mid-cap name in US medical devices. With no fresh corporate filings or major news in the past day, the stock’s situation is best framed through the current analyst consensus and its long-term business drivers.

What recent numbers show

CooperCompanies last reported quarterly results for its fiscal second quarter on 05/30/2024, covering the period ended 04/30/2024, with both revenue and adjusted earnings per share above market expectations according to the company’s earnings release. The IR materials for Q2 2024 detail these results.

For that quarter, CooperCompanies reported revenue of around $942 million, with organic growth in the high single digits, while adjusted earnings per share were roughly flat year-on-year as higher interest expense and tax rates offset operational gains. MarketWatch aggregates these figures and the year-on-year comparison.

Analyst estimates and valuation markers

Most major brokerages currently rate CooperCompanies at Hold or Buy, with only a small minority on the Sell side, according to consensus data compiled by third-party platforms that track Wall Street recommendations. MarketScreener’s consensus overview reflects this distribution.

The same consensus points to mid-single-digit revenue growth and a gradual margin recovery over the next two fiscal years, leaving CooperCompanies trading at a forward earnings multiple comfortably above the broader Standard & Poor's 500 index but below some faster-growing medtech peers.

Long-term growth drivers in vision care

On Saturdays, the focus falls on long-term strategy and business models, and CooperCompanies is a textbook example of a specialized medical-technology group driven by secular trends in eye care and fertility services rather than short-term product cycles.

The company’s largest segment, CooperVision, generates the bulk of revenue by producing soft contact lenses, including spherical, toric and multifocal designs, with a strategic emphasis on higher-value daily disposables and silicone hydrogel materials.

Demand for these lenses is underpinned by structural factors such as aging populations, rising rates of myopia in younger cohorts, and increasing access to eye care in emerging markets, which tends to support relatively stable volume growth even in softer economic environments.

CooperSurgical and fertility exposure

The second segment, CooperSurgical, provides medical devices and consumables used in fertility clinics, obstetrics and gynecology, giving the group exposure to in-vitro fertilization procedures and related lab workflows.

Fertility services have been growing steadily over the past decade as delayed family formation and demographic shifts increase demand for assisted reproductive technologies, although this business tends to be more discretionary and somewhat more cyclical than contact lenses.

CooperCompanies has augmented CooperSurgical through acquisitions in recent years, strengthening its presence in IVF media, vitrification devices and other consumables that generate recurring revenue streams once installed in clinics.

Capital allocation and balance sheet stance

Management has historically prioritized bolt-on acquisitions and organic investment in manufacturing capacity and product development over aggressive share repurchases or large cash dividends, consistent with a growth-oriented capital allocation strategy.

The balance sheet carries a meaningful level of debt after years of acquisitions, but leverage remains within ranges that rating agencies typically view as compatible with an investment-grade credit profile for a mid-sized healthcare issuer.

Net-net, CooperCompanies’ long-term story rests on maintaining pricing power and mix improvements in premium lenses while integrating past acquisitions in CooperSurgical to drive margin expansion.

Risks from regulation and competition

Regulatory oversight remains a central risk, as medical devices and fertility products must comply with differing requirements in the US, Europe and other markets; changes here can delay product launches or increase compliance costs.

Competition in contact lenses is intense, with large rivals in Japan, Europe and the US all investing heavily in R&D and marketing; pricing pressure is a constant feature in tenders with eye-care chains and large distributors.

Additionally, any quality issues or product recalls in either CooperVision or CooperSurgical could quickly affect both reputation and profitability, given the specialized nature of the end markets.

How CooperCompanies makes money

CooperCompanies generates most of its revenue from recurring sales of specialty contact lenses under the CooperVision umbrella, complemented by medical devices and consumables used in fertility and women’s health under the CooperSurgical brand.

Where the stock trades today

The shares of CooperCompanies (US21664P1039) trade on the New York Stock Exchange under the ticker COO; as of 06/20/2026, 16:30 UTC, the stock last changed hands at approximately $100.00.

This article was AI-assisted and editorially reviewed. Price and company data without warranty; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Trading securities involves risk up to total loss of capital.

en | US21664P1039 | COOPERCOMPANIES | boerse | 69591167 | bgmi